Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 2/2021

01-03-2021 | Disseminated Intravascular Coagulation | IM - REVIEW

COVID-19 coagulopathy: is it disseminated intravascular coagulation?

Authors: Marcel Levi, Toshiaki Iba

Published in: Internal and Emergency Medicine | Issue 2/2021

Login to get access

Abstract

One of the significant complications of severe COVID-19 infections is a coagulopathy that seems to be related to the occurrence of venous and arterial thromboembolic disease. The coagulation changes mimic but are not identical to disseminated intravascular coagulation (DIC). The vast majority of patients with COVID-19 do not meet the criteria for usual forms of DIC. In addition, there seem to be features of a strong local pulmonary thrombotic microangiopathy and direct endothelial cell infection and injury by the virus that affect the coagulopathic response to severe COVID-19. It seems COVID-19 leads to a distinct intravascular coagulation syndrome that may need separate diagnostic criteria.
Literature
1.
Mason RJ (2020) Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 55:2000607CrossRef
2.
Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273CrossRef
3.
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062CrossRef
4.
Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847CrossRef
5.
Klok FA, Kruip M, van der Meer NJM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147CrossRef
6.
Marietta M, Coluccio V, Luppi M (2020) COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med 15:1375–1387CrossRef
7.
Gando S, Levi M, Toh CH (2016) Disseminated intravascular coagulation. Nature Rev Dis Prim 2:16037CrossRef
8.
Levi M (2020) COVID-19 coagulopathy vs disseminated intravascular coagulation. Blood Adv 4:2850CrossRef
9.
Levi M, Thachil J (2020) Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost 46:781–784CrossRef
10.
Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395:497–506CrossRef
11.
Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720CrossRef
12.
Zhang L, Yan X, Fan Q et al (2020) d-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18:1324–1329CrossRef
13.
Lippi G, Plebani M, Henry BM (2020) Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 506:145–148CrossRef
14.
Brogaard Larsen J, Pasalic L, Hvas AM. Platelets in Coronavirus Disease. Seminars in Thrombosis & Hemostasis 2020.
15.
Favaloro EJ, Lippi G (2020) Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part I. Semin Thromb Hemost 46:757–762CrossRef
16.
Ranucci M, Ballotta A, Di Dedda U et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 18:1747–1751CrossRef
17.
Gralinski LE, Bankhead A, Jeng S et al (2013) Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 4:e00271-e313CrossRef
18.
Liu ZH, Wei R, Wu YP et al (2005) Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. Biomed Environ Sci BES 18:260–264PubMed
19.
Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J (2020) Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine 59:102969CrossRef
20.
Iba T, Levy JH, Levi M, Thachil J (2020) Coagulopathy in COVID-19. J Thromb Haemost 18:2103–2109CrossRef
21.
Coccheri S (2020) COVID-19: The crucial role of blood coagulation and fibrinolysis. Intern Emerg Med 15:1369–1373CrossRef
22.
Deng Y, Liu W, Liu K et al (2020) Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl) 133:1261–1267CrossRef
23.
Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRef
24.
Fox SE, Atmakbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS (2020) Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. MedRxiv 22:358
25.
George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666CrossRef
26.
Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D (2020) Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med 15:861–863CrossRef
27.
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020.
28.
Levi M, Scully M, Singer M (2018) The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 16:646–651CrossRef
Metadata
Title
COVID-19 coagulopathy: is it disseminated intravascular coagulation?
Authors
Marcel Levi
Toshiaki Iba
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2021
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-020-02601-y

Other articles of this Issue 2/2021

Internal and Emergency Medicine 2/2021 Go to the issue

CE-Research Letter to the Editor

The BRASH syndrome: an interaction of bradycardia, renal failure, AV block, shock and hyperkalemia

IM - CASE RECORD

The doctor who stared at schistocytes: an intriguing case of suspected thrombotic microangiopathic anemia

IM - ORIGINAL

Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign

IM - ORIGINAL

Postoperative atrial fibrillation is related to a worse outcome in patients undergoing surgery for hip fracture

CE - LETTER TO THE EDITOR

Diagnostic reasoning in internal medicine: a practical reappraisal: comment

IM - ORIGINAL

HLA-B*51 allelic and carrier frequency in Kazakhstan: insights into Behçet’s disease prevalence in Central Asia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits